Seikagaku Overview

  • Year Founded
  • 1947

Year Founded

  • Status
  • Public

  • Employees
  • 1,260

Employees

  • Stock Symbol
  • 4548

Stock Symbol

  • Investments
  • 1

  • Share Price
  • $3.37
  • (As of Friday Closing)

Seikagaku General Information

Description

Seikagaku Corp makes and sells pharmaceuticals and medical devices related to glycoconjugates. The firm operates in two segments: pharmaceutical and LAL. The pharmaceutical segment contributes the majority of revenue. This business sells pharmaceutical products made from hyaluronic acid, a main component of glycoconjugates, as well as medical devices and bulk products. The LAL segment manufactures endotoxin-detecting reagents made from limulus amebocyte lysate that are used to control quality in the pharmaceutical manufacturing process. Seikagaku generates the majority of its sales in Japan.

Contact Information

Website
www.seikagaku.co.jp
Formerly Known As
Kosei Suisan K.K., Seikagaku Kenkyusho, Suisan
Ownership Status
Publicly Held
Financing Status
Corporation
Corporate Office
  • Marunouchi Center Building, 10th Floor
  • 6-1, Marunouchi 1-chome, Chiyoda-ku
  • Tokyo, 100-0005
  • Japan
+81
Primary Industry
Diagnostic Equipment
Other Industries
Biotechnology
Therapeutic Devices
Stock Exchange
TKS
Vertical(s)
Manufacturing
Corporate Office
  • Marunouchi Center Building, 10th Floor
  • 6-1, Marunouchi 1-chome, Chiyoda-ku
  • Tokyo, 100-0005
  • Japan
+81

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Seikagaku Stock Performance

As of 13-Nov-2026, Seikagaku’s stock price is $3.37. Its current market cap is $184M with 54.6M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$3.37 $3.37 $3.30 - $5.16 $184M 54.6M 355K

Seikagaku Financials Summary

As of 30-Sep-2026, Seikagaku has a trailing 12-month revenue of $235M.

In Thousands,
USD 		TTM 30-Sep-2026 FY 2026 31-Mar-2026 FY 2025 31-Mar-2025 FY 2024 31-Mar-2024
EV 120,329 164,737 152,811 131,814
Revenue 234,802 243,125 258,193 250,627
EBITDA 25,492 23,752 24,722 22,202
Net Income 146 9,773 7,961 15,129
Total Assets 536,813 540,129 560,483 540,436
Total Debt 2,230 2,227 2,539 2,616
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Seikagaku Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA		 Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Seikagaku‘s full profile, request access.

Request a free trial

Seikagaku Patents

  • 3,283

    Total Documents Applications and Grants

  • Total Patents Families

  • 1,367

    Granted

  • 133

    Pending

  • Expiring in next 12 mo

Seikagaku Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
US-D1118920-S1 Plunger rod for syringe Active 19-Jan-2024
EP-4678120-A1 Administering device and medical implement Pending 09-Mar-2023
WO-2024185874-A1 Administering device and medical implement Inactive 09-Mar-2023
US-D1071172-S1 Medical powder ejection device Active 20-Dec-2022
US-D1076069-S1 Cover for medical powder spreading device Active 22-Apr-2022
To view Seikagaku’s complete patent history, request access »

Seikagaku Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Seikagaku Acquisitions (1)

Seikagaku’s most recent deal was a Merger/Acquisition with Dalton Pharma Services for . The deal was made on 28-Feb-2020.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Dalton Pharma Services 28-Feb-2020 Merger/Acquisition Drug Discovery
To view Seikagaku’s complete acquisitions history, request access »

Ready to get started?

Request a free trial

Seikagaku ESG

Risk Overview

Risk Rating

Updated March, 31, 2026

31.29 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 14,271

Rank

Percentile

Pharmaceuticals

Industry

of 908

Rank

Percentile

Pharmaceuticals

Subindustry

of 406

Rank

Percentile

To view Seikagaku’s complete esg history, request access »

Seikagaku Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Dalton Pharma Services Toronto, Canada 1986

Seikagaku FAQs

  • When was Seikagaku founded?

    Seikagaku was founded in 1947.

  • Where is Seikagaku headquartered?

    Seikagaku is headquartered in Tokyo, Japan.

  • What is the size of Seikagaku?

    Seikagaku has 1,260 total employees.

  • What industry is Seikagaku in?

    Seikagaku’s primary industry is Diagnostic Equipment.

  • Is Seikagaku a private or public company?

    Seikagaku is a Public company.

  • What is Seikagaku’s stock symbol?

    The ticker symbol for Seikagaku is 4548.

  • What is the current stock price of Seikagaku?

    As of 13-Nov-2026 the stock price of Seikagaku is $3.37.

  • What is the current market cap of Seikagaku?

    The current market capitalization of Seikagaku is $184M.

  • What is Seikagaku’s current revenue?

    The trailing twelve month revenue for Seikagaku is $235M.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more

  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process